findmyKOL
Clinical trialNCT06374459RecruitingPhase 1/PHASE2Interventional

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

SponsorWashington University School of MedicineEnrollment152Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • the University of Kansas Cancer Center

    Westwood, Kansas, United States

    Qamar Khan, M.D.
    Recruiting
  • Mayo Clinic

    Rochester, Minnesota, United States

    Matthew Goetz, M.D.
    Not, yet, recruiting
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Andrew Davis, M.D.Ashley Frith, M.D., Ph.D.Cynthia X Ma, M.D., Ph.D.Faisal Fa'ak, M.D.Foluso Ademuyiwa, M.D.Jingqin (Rosy) Luo, Ph.D.Lindsay Peterson, M.D.Nusayba Bagegni, M.D.Rama Suresh, M.D.Roberto Civitelli, M.D.Ron Bose, M.D., Ph.D.Sheila Stewart, Ph.D.
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jan 2025
Primary completion
31 May 2032
Completion
31 May 2032
Last update posted
20 Apr 2026
Registered enrollment
152
Registry id
NCT06374459

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.